Regresa al Registro Simple

 
dc.contributorVall d'Hebron Barcelona Hospital Campus
dc.contributor.authorFelip Font, Enriqueta
dc.contributor.authorMorgensztern, Daniel
dc.contributor.authorTrigo, José Manuel
dc.contributor.authorMoreno, Victor
dc.contributor.authorCurigliano, Giuseppe
dc.contributor.authorRutkowski, Piotr
dc.date.accessioned2022-08-10T06:25:51Z
dc.date.available2022-08-10T06:25:51Z
dc.date.issued2022-04
dc.identifier.citationFelip E, Moreno V, Morgensztern D, Curigliano G, Rutkowski P, Trigo JM, et al. First-in-human, open-label, phase 1/2 study of the monoclonal antibody programmed cell death protein-1 (PD-1) inhibitor cetrelimab (JNJ-63723283) in patients with advanced cancers. Cancer Chemother Pharmacol. 2022 Apr;89:499–514.
dc.identifier.issn1432-0843
dc.identifier.urihttps://hdl.handle.net/11351/7973
dc.descriptionMelanoma; Eficacia del inhibidor del anticuerpo monoclonal PD-1; Farmacocinética/farmacodinamia
dc.language.isoeng
dc.publisherSpringer
dc.relation.ispartofseriesCancer Chemotherapy and Pharmacology;89
dc.rightsAttribution 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.sourceScientia
dc.subjectCàncer - Tractament
dc.subjectAnticossos monoclonals - Ús terapèutic - Eficàcia
dc.subject.meshNeoplasms
dc.subject.mesh/drug therapy
dc.titleFirst-in-human, open-label, phase 1/2 study of the monoclonal antibody programmed cell death protein-1 (PD-1) inhibitor cetrelimab (JNJ-63723283) in patients with advanced cancers
dc.typeinfo:eu-repo/semantics/article
dc.identifier.doi10.1007/s00280-022-04414-6
dc.subject.decsneoplasias
dc.subject.decs/farmacoterapia
dc.relation.publishversionhttps://doi.org/10.1007/s00280-022-04414-6
dc.type.versioninfo:eu-repo/semantics/publishedVersion
dc.audienceProfessionals
dc.contributor.organismesInstitut Català de la Salut
dc.contributor.authoraffiliation[Felip E] Unitat de Càncer Toràcic, Servei d’Oncologia Mèdica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. [Moreno V] Phase 1 Trials Unit, START MADRID-FJD, Hospital Fundación Jiménez Díaz Medical Oncology Division, Madrid, Spain. [Morgensztern D] Division of Oncology, Section of Medical Oncology, Washington University School of Medicine, St. Louis, MO, USA. [Curigliano G] Division of Early Drug Development, European Institute of Oncology, IRCCS and University of Milano, Milan, Italy. [Rutkowski P] Department of Soft Tissue/Bone Sarcoma and Melanoma, Maria Skłodowska-Curie National Research Institute of Oncology, Warsaw, Poland. [Trigo JM] Department of Medical Oncology, Hospital Universitario Virgen de La Victoria y Regional, Málaga, Spain
dc.identifier.pmid35298698
dc.identifier.wos000770203700002
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess


Ficheros en el ítem

Thumbnail

Este ítem aparece en la(s) siguiente(s) colección(ones)

Regresa al Registro Simple